Organ preservation with total neoadjuvant therapy in early‐stage rectal cancer: A statewide analysis
Colorectal Disease · 2026-04 · 28 (4)
DOI: 10.1111/codi.70446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Colorectal Disease, online erschienen am 03.04.2026. Verfasst von Zachary Bunjo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoadjuvant Therapy, Adenocarcinoma, Organ Sparing Treatments. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The standard treatment for early‐stage (cT2‐3N0) rectal adenocarcinoma is upfront Total Mesorectal Excision (TME), but the desire for organ preservation has seen the increasing use of neoadjuvant therapy in these patients. Owing to its likely higher complete response rate, Total Neoadjuvant Therapy (TNT) is an attractive but understudied option. This study aimed to determine outcomes in patients with early‐stage rectal cancer undergoing TNT.
Methods
This was a retrospective study of patients with cT2‐3N0M0 rectal adenocarcinoma who underwent TNT instead of upfront surgery from 2019 to 2025 in South Australia. TNT comprised long‐course chemoradiotherapy followed by up to 8 cycles of FOLFOX or 6 cycles of CAPOX. Patients with cCR were offered watch and wait (W&W) surveillance. The outcomes of interest included cCR rate, regrowth rate, local and distant recurrences (LR and DR) and 3‐year survival.
Results
Thirty‐nine patients were included, with mean tumour distance 4 cm from the anal verge. The median follow‐up was 41 months (IQR 26–61) and 53.8% had completed at least 3 years of follow‐up. Thirty‐one patients (79.5%) achieved a cCR and proceeded to W&W. The regrowth rate was 16.1%; none experienced a LR and three had a DR. The 3‐year DFS in the overall cohort was 94.1% (95% CI 86.3%–100%) and all patients were alive up to 3 years of follow‐up. The rate of Grade 3 or higher chemotherapy‐related toxicity was 25.6% and there were no deaths.
Conclusion
Patients receiving TNT for early‐stage rectal cancer had a very high cCR rate and associated high organ preservation rate. This approach has potential quality of life advantages compared with surgery, with acceptable oncological and toxicity profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
- Discipline of Surgery, Faculty of Health and Medical Sciences, School of Medicine, Adelaide University, Adelaide, South Australia, Australia.
- Department of Surgery, Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia.
- Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
- Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
- Department of Surgery, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia.
ORCID-Profile: Zachary Bunjo, Thuy-My Nguyen, Elizabeth Murphy, Tarik Sammour
Zitieren
APA
Bunjo, Z., Fitzsimmons, T., Nguyen, T. M., Penniment, M., Selva-Nayagam, S., Tonkin, D., Sia, T. C., Murphy, E., Thomas, M., & Sammour, T. (2026). Organ preservation with total neoadjuvant therapy in early‐stage rectal cancer: A statewide analysis. Colorectal Disease, 28(4). https://doi.org/10.1111/codi.70446
Vancouver
Bunjo Z, Fitzsimmons T, Nguyen TM, Penniment M, Selva-Nayagam S, Tonkin D, et al. Organ preservation with total neoadjuvant therapy in early‐stage rectal cancer: A statewide analysis. Colorectal Disease. 2026;28(4). doi:10.1111/codi.70446
BibTeX
@article{Bunjo2026,
author = {Bunjo, Zachary and Fitzsimmons, Tracy and Nguyen, Thuy-My and Penniment, Michael and Selva-Nayagam, Sudarshan and Tonkin, Darren and Sia, Tiong Cheng and Murphy, Elizabeth and Thomas, Michelle and Sammour, Tarik},
title = {Organ preservation with total neoadjuvant therapy in early‐stage rectal cancer: A statewide analysis},
journal = {Colorectal Disease},
year = {2026},
volume = {28},
number = {4},
doi = {10.1111/codi.70446}
}
EUVIMED